186 related articles for article (PubMed ID: 27741105)
1. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.
Huang L; Wang SA; Konoplev S; Bueso-Ramos CE; Thakral B; Miranda RN; Jabbour E; Medeiros LJ; Kanagal-Shamanna R
Medicine (Baltimore); 2016 Oct; 95(41):e4934. PubMed ID: 27741105
[TBL] [Abstract][Full Text] [Related]
2. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
[TBL] [Abstract][Full Text] [Related]
3. Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.
Zhao DD; Zhang L; Li WQ; Duan MH; Zhuang JL; Zhou DB
Chin Med J (Engl); 2019 Aug; 132(16):2002-2003. PubMed ID: 31335472
[No Abstract] [Full Text] [Related]
4. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
5. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis.
Berezowska S; Flaig MJ; Ruëff F; Walz C; Haferlach T; Krokowski M; Kerler R; Petat-Dutter K; Horny HP; Sotlar K
Mod Pathol; 2014 Jan; 27(1):19-29. PubMed ID: 23807778
[TBL] [Abstract][Full Text] [Related]
6. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
7. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
8. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
[TBL] [Abstract][Full Text] [Related]
9. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
10. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
12. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
14. Mastocytosis and related disorders.
Chiu A; Orazi A
Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
[TBL] [Abstract][Full Text] [Related]
15. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
[TBL] [Abstract][Full Text] [Related]
17. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
Horny HP; Sotlar K; Sperr WR; Valent P
J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
[TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review.
Stoecker MM; Wang E
Arch Pathol Lab Med; 2012 Jul; 136(7):832-8. PubMed ID: 22742558
[TBL] [Abstract][Full Text] [Related]
20. Skin lesions and mast cells.
Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
